📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts. (2021)

First Author: Derikx LAAP

Attributed to: Precision Medicine in Crohn's Disease and Ulcerative Colitis: Predicting Disease Flare and Disease progression funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/ecco-jcc/jjab100

PubMed Identifier: 34089587

Publication URI: http://europepmc.org/abstract/MED/34089587

Type: Journal Article/Review

Volume: 15

Parent Publication: Journal of Crohn's & colitis

Issue: 12

ISSN: 1873-9946